We are live on ! Find out more

2,874 hedge funds and large institutions have $105B invested in Pfizer in 2024 Q2 according to their latest regulatory filings, with 212 funds opening new positions, 1,183 increasing their positions, 1,240 reducing their positions, and 172 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 212 | Existing positions closed: 172

6% more funds holding in top 10

Funds holding in top 10: 3133 (+2)

0% less funds holding

Funds holding: 2,8752,874 (-1)

0% less capital invested

Capital invested by funds: $105B → $105B (-$332M)

5% less repeat investments, than reductions

Existing positions increased: 1,183 | Existing positions reduced: 1,240

1.16% less ownership

Funds ownership: 67.24%66.08% (-1.2%)

40% less call options, than puts

Call options by funds: $2.36B | Put options by funds: $3.9B

Holders
2,874
Holders Change
-1
Holders Change %
-0.03%
% of All Funds
41.5%
Holding in Top 10
33
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+6.45%
% of All Funds
0.48%
New
212
Increased
1,183
Reduced
1,240
Closed
172
Calls
$2.36B
Puts
$3.9B
Net Calls
-$1.54B
Net Calls Change
+$77.4M
Name Holding Trade Value Shares
Change
Change in
Stake
JIC
1026
Joel Isaacson & Co
New York
$2.13M +$3.88K +141 +0.2%
WCM
1027
Windward Capital Management
California
$2.13M -$73.1K -2,654 -3%
TPWA
1028
TRUE Private Wealth Advisors
Oregon
$2.12M +$235K +8,550 +13%
TA
1029
TKG Advisors
Indiana
$2.11M -$18.6K -674 -0.9%
AWP
1030
Ascent Wealth Partners
New York
$2.11M +$234K +8,516 +13%
FBT
1031
First Bank & Trust
South Dakota
$2.11M +$95K +3,451 +5%
CC
1032
Chicago Capital
Illinois
$2.1M +$70.9K +2,575 +4%
BCM
1033
Blume Capital Management
California
$2.1M +$253K +9,195 +14%
PTC
1034
Private Trust Company
Ohio
$2.1M +$130K +4,731 +7%
BC
1035
Bridgefront Capital
Texas
$2.09M +$1.44M +52,419 +234%
CSC
1036
Caldwell Sutter Capital
California
$2.09M +$30.5K +1,108 +2%
RIM
1037
Redwood Investment Management
Arizona
$2.09M -$194K -7,041 -9%
SCM
1038
Stonebridge Capital Management
California
$2.09M -$4.27K -155 -0.2%
SBIA
1039
Sheaff Brock Investment Advisors
Indiana
$2.08M -$98.3K -3,571 -5%
CIA
1040
Cohen Investment Advisors
New Hampshire
$2.08M -$198K -7,198 -10%
NERM
1041
New England Research & Management
Illinois
$2.08M -$166K -6,017 -7%
BA
1042
Bridgewater Advisors
New York
$2.07M +$132K +4,779 +7%
AIM
1043
AHL Investment Management
Florida
$2.07M +$25.8K +936 +1%
XT
1044
XTX Topco
Cayman Islands
$2.07M +$1.37M +49,851 +207%
ORG
1045
Optimist Retirement Group
Washington
$2.07M +$226K +8,195 +12%
SFO
1046
Stokes Family Office
Louisiana
$2.06M +$12.8K +466 +0.6%
BOSSRA
1047
B.O.S.S. Retirement Advisors
Utah
$2.06M +$1.13M +40,947 +126%
HI
1048
Harbour Investments
Wisconsin
$2.05M +$254K +9,216 +14%
PS
1049
Pensionfund Sabic
Netherlands
$2.04M
SHFA
1050
SS&H Financial Advisors
Michigan
$2.03M -$168K -6,117 -8%

PFE Hedge Fund Activity: Q2 2024 in Review

2,874 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2024, worth a combined $105B — down 0.32% from $105B a quarter earlier.

Buyers outnumbered sellers: 212 funds opened new PFE positions and 172 closed out — a net gain of 40 holders — while 1,183 added to existing stakes and 1,240 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $346M. The largest seller was Capital World Investors, cutting an estimated $675M.

  • 2,874 institutional investors held Pfizer (PFE) as of Q2 2024, down from 2,875 in Q1 2024.
  • Funds reported $105B of Pfizer stock for Q2 2024, down 0.32% quarter-over-quarter.
  • 212 funds opened new Pfizer positions in Q2 2024 and 172 closed out, a net change of +40 holders.
  • The largest Pfizer buyer in Q2 2024 was Goldman Sachs, an estimated $346M added.
  • The largest Pfizer seller in Q2 2024 was Capital World Investors, an estimated $675M sold.

Based on aggregated 13F filings for Q2 2024.